Pathogenesis of E‐Cigarette Vaping Product Use‐Associated Lung Injury (EVALI)

Petrache, Irina; Gupta, Arnav; Hume, Patrick S.; Rivera, T.; Schweitzer, Kelly S.; Chu, Hong Wei

doi:10.1002/cphy.c220022

Cited by 1 publication

(1 citation statement)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, data on EVALI were reported, too, during pandemic years and we identified nine studies concerning the use of steroids as part of EVALI management within our time frame of research. EVALI represents a severe inflammatory syndrome that was described for the first time in 2019 at teenagers who were admitted for different manifestations of respiratory insufficiency in relationship with e-cigarette use [34].…”

Section: Evali and The Use Of Systemic Steroidsmentioning

confidence: 99%

Metabolic and Other Endocrine Elements with Regard to Lifestyle Choices: Focus on E-Cigarettes

Osman,

Petrescu,

Tuculină

et al. 2023

Metabolites

View full text Add to dashboard Cite

Our objective was to overview recent data on metabolic/endocrine disorders with respect to e-cigarette (e-cig) use. This is a narrative review; we researched English, full-length, original articles on PubMed (between January 2020 and August 2023) by using different keywords in the area of metabolic/endocrine issues. We only included original clinical studies (n = 22) and excluded case reports and experimental studies. 3 studies (N1 = 22,385; N2 = 600,046; N3 = 5101) addressed prediabetes risk; N1 showed a 1.57-fold increased risk of dual vs. never smokers, a higher risk that was not confirmed in N2 (based on self-reported assessments). Current non-smokers (N1) who were dual smokers still have an increased odd of prediabetes (a 1.27-fold risk increase). N3 and another 2 studies addressed type 2 diabetes mellitus (DM): a lower prevalence of DM among dual users (3.3%) vs. cigarette smoking (5.9%) was identified. 6 studies investigated obesity profile (4 of them found positive correlations with e-cig use). One study (N4 = 373,781) showed that e-cig use was associated with obesity in the general population (OR = 1.6, 95%CI: 1.3–2.1, p < 0.05); another (N5 = 7505, 0.82% were e-cig-only) showed that obesity had a higher prevalence in dual smokers (51%) vs. cig-only (41.2%, p < 0.05), while another (N6 = 3055) found that female (not male) e-cig smokers had higher body mass index vs. non-smokers. Data on metabolic syndrome (MS) are provided for dual smokers (n = 2): one case–control study found that female dual smokers had higher odds of MS than non-smokers. The need for awareness with respect to potential e-cig-–associated medical issues should be part of modern medicine, including daily anamnesis. Whether the metabolic/endocrine frame is part of the general picture is yet to be determined. Surveillance protocols should help clinicians to easily access the medical background of one subject, including this specific matter of e-cig with/without conventional cigarettes smoking and other habits/lifestyle elements, especially when taking into consideration metabolism anomalies.

show abstract

Section: Evali and The Use Of Systemic Steroidsmentioning

confidence: 99%